74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Viking Therapeutics Inc
Closed
SectorHealthcare
25.59 -0.81
Overview
Share price change
24h
Min
24.87
Max
26.54
Income | -10M -35M |
|---|---|
EPS | -0.32 |
Employees | 36 |
EBITDA | -9.6M -46M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +248.66% upside |
Next Earnings | 23 Jul 2025 |
|---|
Market Cap | -570M 2.7B |
|---|---|
Previous open | 26.4 |
Previous close | 25.59 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Viking Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Viking Therapeutics Inc Forecast
Price Target
By TipRanks
248.66% upside
12 Months Forecast
Average 89.92 USD 248.66%
High 125 USD
Low 30 USD
Based on 17 Wall Street analysts offering 12 month price targets forViking Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
